Skip to main content

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

Author(s): Wong, C.; Laddha, S.V.; Tang, L.; Vosburgh, E.; Levine, Arnold J.; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1zn3t
Abstract: Endogenous c-MYC (MYC) has been reported to be a potential pharmacological target to trigger ubiquitous tumor regression of pancreatic neuroendocrine tumors (PanNETs) and lung tumors. Recently inhibitors of bromodomain and extra-terminal (BET) family proteins have shown antitumor effects through the suppression of MYC in leukemia and lymphoma. In this paper, we investigated the antitumor activity of a BET protein bromodomain inhibitor (BETi) CPI203 as a single agent and in combination with rapamycin in human PanNETs. We found that exposure of human PanNET cell lines to CPI203 led to downregulation of MYC expression, G1 cell cycle arrest and nearly complete inhibition of cell proliferation. In addition, overexpression of MYC suppressed the growth inhibition caused by CPI203 and knockdown of MYC phenocopied the effects of CPI203 treatment. These findings indicate that suppression of MYC contributed to the antiproliferative effects of BETi inhibition in human PanNET cells. Importantly, CPI203 treatment enhanced the antitumor effects of rapamycin in PanNET cells grown in monolayer and in three-dimensional cell cultures, as well as in a human PanNET xenograft model in vivo. Furthermore, the combination treatment attenuated rapamycin-induced AKT activation, a major limitation of rapamycin therapy. Collectively, our data suggest that targeting MYC with a BETi may increase the therapeutic benefits of rapalogs in human PanNET patients. This provides a novel clinical strategy for PanNETs, and possibly for other tumors as well.
Publication Date: Oct-2014
Electronic Publication Date: 9-Oct-2014
Citation: Wong, C., Laddha, S.V., Tang, L., Vosburgh, E., Levine, A.J., Normant, E., Sandy, P., Harris, C.R., Chan, C.S., Xu, E.Y. (2014). The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death & Disease, 5 (10), e1450 - e1450. doi:10.1038/cddis.2014.396
DOI: doi:10.1038/cddis.2014.396
EISSN: 2041-4889
Pages: e1450 - e1450
Type of Material: Journal Article
Journal/Proceeding Title: Cell Death & Disease
Version: Final published version. This is an open access article.



Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.